Answers are grounded in this paper and cite their sources.
Upper tract urothelial carcinoma (UTUC) is a relatively uncommon yet highly aggressive malignancy associated with a substantial risk of recurrence following radical nephroureterectomy (RNU). Although the TNM staging system remains the cornerstone of postoperative risk stratification, marked prognostic heterogeneity persists among patients with identical stage, indicating that anatomical tumor burden alone cannot fully capture individual recurrence risk. This study aimed to develop and internally assess an integrated prognostic model that combines systemic inflammation, tumor biology, and anatomical tumor burden to improve recurrence prediction after RNU. We retrospectively analyzed 157 consecutive UTUC patients who underwent RNU at our institution between October 2019 and January 2026. The systemic immune–inflammation index (SII) was derived from preoperative routine blood counts, and HER2 expression was determined by immunohistochemistry on surgical specimens. Patients were classified into three SII–HER2 risk groups: low–risk (low SII and HER2–negative), intermediate–risk (either factor), and high–risk (high SII and HER2–positive). The optimal SII cutoff (584.20) was determined using a survival–based log–rank method. A multivariable Cox proportional hazards model incorporating TNM stage and SII–HER2 classification was developed. Model performance was evaluated using Harrell’s C–index, time–dependent AUC, calibration curves, and decision curve analysis, with internal assessment via 1000 bootstrap resamples of the final fitted model. During a median follow–up of 26.6 months, 63 patients (40.1%) developed any recurrence. In the final multivariable model, TNM stage III/IV (vs. I/II; HR = 2.596, 95% CI: 1.356–4.972) and SII–HER2 high–risk group (vs. low–risk; HR = 6.551, 95% CI: 2.701–15.893) were independent predictors of recurrence, whereas the intermediate–risk group showed a borderline association (HR = 2.190, 95% CI: 0.777–6.170; P = 0.138). The TNM–SII–HER2 model showed improved discrimination compared with TNM staging alone (C–index: 0.737 [SE = 0.030] vs. 0.657), and bootstrap internal assessment of the final fitted model yielded a corrected C–index of 0.733. Time–dependent AUCs for 1–, 2–, and 3–year recurrence–free survival were 0.736, 0.781, and 0.857, respectively. Calibration curves showed acceptable agreement at 2 and 3 years, and decision curve analysis suggested potential clinical utility of the model. The TNM–SII–HER2 model combines TNM stage with a derived three–level SII–HER2 categorical variable to improve recurrence risk stratification following RNU for UTUC. This model provides incremental prognostic value beyond conventional TNM staging and may help identify patients who may be considered for closer postoperative surveillance. Prospective multicenter studies are needed to further validate its clinical utility and generalizability.
No takes yet. Share an insight, caveat, or question.
郭宇璇 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: